CryerPE: Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes, 2014; 63:2188–2195.
2.
SvendsenPA, LauritzenT, SøegaardU, NerupJ: Glycosylated haemoglobin and steady-state mean blood glucose concentration in Type 1 (insulin-dependent) diabetes. Diabetologia, 1982; 23:403–405.
3.
SantiagoJV: Lessons from the diabetes control and complications trial. Diabetes, 1993; 42:1549–1554.
4.
KovatchevBP: Metrics for glycaemic control—from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol, 2017; 13:425–436.
5.
KovatchevB, CobelliC: Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care, 2016; 39:502–510.
6.
ServiceFJ, MolnarGD, RosevearJW, et al.: Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes, 1970; 19:644–655.
7.
ServiceFJ: Comment on Kovatchev and Cobelli. Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care, 2016; 39:502–510.
8.
KovatchevB, CobelliC: Response to Comment on Kovatchev and Cobelli. Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care, 2016; 39:502–510.
9.
DanneT, NimriR, BattelinoT, et al.: International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care, 2017; 40:1631–1640.
10.
HermanidesJ, VriesendorpTM, BosmanRJ, et al.: Glucose variability is associated with intensive care unit mortality. Crit Care Med, 2010; 38:838–842.
11.
McDonnellCM, DonathSM, VidmarSI, et al.: A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther, 2005; 7:253–263.
12.
KovatchevBP, CoxDJ, Gonder-FrederickLA, ClarkeW: Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care, 1997; 20:1655–1658.
13.
PeyserTA, BaloAK, BuckinghamBA, et al.: Glycemic variability percentage: a novel method for assessing glycemic variability from continuous glucose monitor data. Diabetes Technol Ther, 2018; 20:6–16.
14.
Dalla ManC, MichelettoF, LvD, et al.: The UVA/PADOVA type 1 diabetes simulator: new features. J Diabetes Sci Technol, 2014; 8:26–34.
15.
EdelmanSV: Regulation catches up to reality. J Diabetes Sci Technol, 2017; 11:160–164.
16.
FDA Advisory Panel Votes to Recommend Non-Adjunctive Use of Dexcom G5 Mobile CGM. Diabetes Technol Ther, 2016; 18:512–516.
17.
VettorettiM, FacchinettiA, SparacinoG, CobelliC: Type 1 diabetes patient decision simulator for in silico testing safety and effectiveness of insulin treatments. IEEE Trans Biomed Eng, 2017. doi: 10.1109/TBME.2017.2746340.
CobelliC, ManCD, PedersenMG, et al.: Advancing our understanding of the glucose system via modeling: a perspective. IEEE Trans Biomed Eng, 2014; 61:1577–1592.
20.
CobelliC, Dalla ManC, ToffoloG, et al.: The oral minimal model method. Diabetes, 2014; 63:1203–1213.
